This document discusses transrectal ultrasound (TRUS)-guided prostate biopsy. It begins with an introduction to declining prostate cancer mortality due to early detection programs using prostate-specific antigen (PSA) testing and TRUS-guided biopsy. It then covers the ultrasonographic anatomy of the prostate visible on TRUS, different TRUS biopsy techniques, indications for biopsy, and advanced ultrasound techniques like color and power Doppler that can help identify areas of neovascularity suspicious for cancer. The document provides a comprehensive overview of how TRUS is used to image the prostate and guide systematic biopsies for prostate cancer detection and diagnosis.
In this presentation we will discuss about the
Anatomy of Prostate
Technique of Transrectal US
Carcinoma Prostate and
Different modes of prostatic biopsy.
In this presentation we will discuss about the
Anatomy of Prostate
Technique of Transrectal US
Carcinoma Prostate and
Different modes of prostatic biopsy.
Ultrasound renal stone differential diagnosis .AHMED ESAWY
renal sinus ultrasound
stone location in calyx
(not in medulla,not in cortex)
echogenic foci
acoustic shadowing
twinkle artifact on colour Doppler
color comet tail artifact
Staghorn calculi
Ultrasound beam-stone angle
Difference between kidney gravel & stone
RENAL ECHOCONCRETION
Vascular Reflectors (Normal or calcified renal vessels are the most
notable and common causes of intrarenal
bright echo reflectors)
Segmental Arteries
Arcuate Arteries
Sinus Vessels
renal vein thrombosis calcification
Calcifications of the branches of the renal artery
Nonvascular Reflectors: Prominent Papillae
Reflectors Within the Renal Parenchyma
Milk of Calcium Cysts
Renal Cortical Calcification
Junctional Parenchymal Line
Angiomyolipomas
Foreign Bodies
Bright echoes within the Renal Parenchyma
medullary nephrocalcinosis
focal pyelonephritis.
Echogenic tips of the renal pyramids apex
Transient pyramidal echogenicity
echogenic neonate renal pyramids (Tamm-Horsfall protein)
fungal balls
blood clots
Renal calcification in infants with Furosemid therapy
Management of renal cell carcinoma - presented at Asian Oncology Summit 2013Siewhong Ho
Dr Ho lectured at the Asian Oncology Summit 2013 in Bangkok on the surgical opinion on management of renal cell carcinoma. He presented to a varied audience of medical oncologist, radiation oncologist, urologists, researchers, para clinical staff and nurses. The most interesting aspect of the lecture was on the role of urologists in management of Stage 4 kidney cancer in the era of 'targeted therapy'. The role of cytoreductive nephrectomy was reviewed potential future developments in this area was discussed
Screening for prostate cancer using PSA has several limitations. It It is an organ specific marker, however, pathology specificity is low (elevated in all, prostatitis, prostatomegaly, prostate cancer, prostate manipulation). Attempts have been made to improve specificity while retaining its sensitivity, e.g. PSA density, PSA % free, PSA velocity, prostate health index (which takes into account p2PSA as well).
after diagnosis of prostate cancer, PSA doubling time is used for assessment of indication of treatment for patients on active surveillance as well as that for indication of salvage treatment for patients with biochemical recurrence after initial treatment.
Ultrasound renal stone differential diagnosis .AHMED ESAWY
renal sinus ultrasound
stone location in calyx
(not in medulla,not in cortex)
echogenic foci
acoustic shadowing
twinkle artifact on colour Doppler
color comet tail artifact
Staghorn calculi
Ultrasound beam-stone angle
Difference between kidney gravel & stone
RENAL ECHOCONCRETION
Vascular Reflectors (Normal or calcified renal vessels are the most
notable and common causes of intrarenal
bright echo reflectors)
Segmental Arteries
Arcuate Arteries
Sinus Vessels
renal vein thrombosis calcification
Calcifications of the branches of the renal artery
Nonvascular Reflectors: Prominent Papillae
Reflectors Within the Renal Parenchyma
Milk of Calcium Cysts
Renal Cortical Calcification
Junctional Parenchymal Line
Angiomyolipomas
Foreign Bodies
Bright echoes within the Renal Parenchyma
medullary nephrocalcinosis
focal pyelonephritis.
Echogenic tips of the renal pyramids apex
Transient pyramidal echogenicity
echogenic neonate renal pyramids (Tamm-Horsfall protein)
fungal balls
blood clots
Renal calcification in infants with Furosemid therapy
Management of renal cell carcinoma - presented at Asian Oncology Summit 2013Siewhong Ho
Dr Ho lectured at the Asian Oncology Summit 2013 in Bangkok on the surgical opinion on management of renal cell carcinoma. He presented to a varied audience of medical oncologist, radiation oncologist, urologists, researchers, para clinical staff and nurses. The most interesting aspect of the lecture was on the role of urologists in management of Stage 4 kidney cancer in the era of 'targeted therapy'. The role of cytoreductive nephrectomy was reviewed potential future developments in this area was discussed
Screening for prostate cancer using PSA has several limitations. It It is an organ specific marker, however, pathology specificity is low (elevated in all, prostatitis, prostatomegaly, prostate cancer, prostate manipulation). Attempts have been made to improve specificity while retaining its sensitivity, e.g. PSA density, PSA % free, PSA velocity, prostate health index (which takes into account p2PSA as well).
after diagnosis of prostate cancer, PSA doubling time is used for assessment of indication of treatment for patients on active surveillance as well as that for indication of salvage treatment for patients with biochemical recurrence after initial treatment.
Reproductive Ultrasonography in animalsSakina Rubab
This is a descriptive presentation on the ultrasonography of female reproductive system as well as male reproductive system too,focusing on disease diagnosis through ultrasonographic images and pregnancy diagnonsis.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
2. Powerpoint Templates
Page 2
INTRODUCTION
• There is a significant decline in prostate
cancer related mortality: d/t early prostate
cancer detection programs.
• Role of PSA screening efforts, introduction
& refinement of systematic transrectal
ultrasonography (TRUS)– guided prostate
biopsy techniques, and increased public
awareness about prostate cancer.
3. Powerpoint Templates
Page 3
• TRUS of the prostate- first described by
Watanabe et al(1968).
• TRUS-guided systematic sextant biopsy
protocol- introduced by Hodge et al(1989).
• TRUS: mainstay of many image-guided
prostate interventions, including prostate
biopsy, brachytherapy, cryotherapy, & high-
intensity focused ultrasonography (HIFU),
evaluation of appropriate patients for treatment
of BPH.
5. Powerpoint Templates
Page 5
• On the basis of pathologic zonal architecture,
prostate is divided into:
Anterior fibromuscular stroma (AFS) that is
devoid of glandular tissue,
transition zone (TZ),
central zone (CZ),
periurethral zone, and
peripheral zone (PZ).
• But these regions are not visible
sonographically as distinct entities.
8. Powerpoint Templates
Page 8
• Normal CZ and PZ(posterior):
majority of adenocarcinomas;
homogeneous echogenic
appearance.
• TZ(anterior) is more heterogeneous.
9. Powerpoint Templates
Page 9
GRAY-SCALE TRUS
• Most common imaging modality for
prostate.
• Most commonly used for:
prostate cancer detection,
evaluation of other conditions such as
infertility,
directing the biopsy of prostate cancer.
10. Powerpoint Templates
Page 10
A, In the transverse plane with the hypoechoic urethra centrally located
(star) and dotted line representing transverse measurement.
B, Midline sagittal view with the hypoechoic urethra running the length of
the gland, D1 represents longitudinal and D2 anteroposterior measurement.
12. Powerpoint Templates
Page 12
• Endorectal probes available in both
side- and end-fire models; transmits
frequencies of 6 to 10 MHz.
• Newer biplane probes provide
simultaneous sagittal and transverse
imaging modes.
13. Powerpoint Templates
Page 13
• Increasing frequency yields increased
resolution.
• The commonly used 7-MHz transducer
produces a high-resolution image with a
focal range from 1 to 4 cm from the
transducer (best for PZ where most
cancers arise).
• Lower frequency transducers (e.g.older 4-
MHz) have a focal range from 2 to 8 cm
but at lower resolution; they improve
anterior delineation of large glands,
increasing the accuracy of volume
measurements, but provide poor internal
architecture visualization.
14. Powerpoint Templates
Page 14
• Medium-gray image of normal PZ
serves as the "reference point" for
judging lesions as hypoechoic (darker
than the normal PZ), isoechoic
(similar to the normal PZ),
hyperechoic (lighter than the normal
PZ), or anechoic (completely black).
• TRUS should be performed in both
transverse and sagittal planes.
15. Powerpoint Templates
Page 15
VOLUME CALCULATION:
• π/6 × transverse diameter × AP
diameter × longitudinal diameter
• Mature average prostate-20-25 g and
remains constant until age 50.
• For more accurate determination of
prostate volume (Brachytherapy),
Planimetry is required.
16. Powerpoint Templates
Page 16
PROSTATE CANCER
IMAGING ON TRUS
• All hypoechoic lesions within the PZ: consider
biopsy.
• A hypoechoic lesion is malignant in 17-57% of
cases, but they are not pathognomonic for
cancer.
• Lack of a distinct hypoechoic focus doesn't
preclude biopsy, as 39% of Ca prostate cases
are isoechoic, & 1% hyperechoic on
conventional gray scale TRUS.
17. Powerpoint Templates
Page 17
• Granulomatous prostatitis, prostatic
infarct & lymphoma- all may produce
hypoechoic lesions.
• Extracapsular extension of prostate
cancer, although not well visualized if
present as a microfocus, is suggested by
a focal loss of the typically bright white
periprostatic fat.
18. Powerpoint Templates
Page 18
Classic hypoechoic peripheral zone (PZ) lesion
(dotted line) in the right midgland that transrectal
ultrasonography–guided biopsy proved to be a
Gleason 3 + 3 = 6 adenocarcinoma.
19. Powerpoint Templates
Page 19
INDICATIONS FOR
PROSTATE BIOPSY
TRUS without Biopsy
• Treatment planning volume measurements:
brachytherapy, cryotherapy, BPH therapy
(e.g.TUMT, RFA)
• Volume measurement during hormonal downsizing
for EBRT or brachytherapy
• Placement of fiducial markers for EBRT
• Evaluation of azoospermia: ejaculatory duct cysts,
seminal vesicle cysts, etc.
• Therapeutic aspiration or unroofing of prostatic
cysts; drainage of prostatic abscess
20. Powerpoint Templates
Page 20
TRUS-Directed Biopsy
• Diagnosis of suspected symptomatic prostate cancer (i.e.,
bone metastasis, cord compression)
• Screening for prostate cancer in asymptomatic patient >
age 50 with > a 10-year life expectancy (if strong family
history or if African-American, consider screening at age
45)
Prostate nodule or significant prostate asymmetry
regardless of PSA level
PSA > 4.0 ng/dL regardless of age
In men < age 60 to 65 years, consider biopsy if PSA > 2.5
ng/dL
If PSA > 0.6 ng/dL at age 40
Increased PSA velocity (>0.75 ng/dL/year)
Free PSA in considering initial biopsy with PSA < 10
ng/mL: >25% no biopsy; >10% and <15%, consider
biopsy; <10%, biopsy
21. Powerpoint Templates
Page 21
• Prior to intervention in symptomatic
BPH (e.g., surgical therapy or initiation
of 5α-reductase inhibitors)
• Prior to cystoprostatectomy or
orthotopic urinary diversion
• To diagnose failed radiation therapy
before use of second-line therapy
• Follow-up biopsy (3-6 months) after
diagnosis of high-grade PIN or ASAP.
22. Powerpoint Templates
Page 22
• Data from the Prostate Cancer
Prevention Trial have shown that no safe
PSA threshold can rule out prostate
cancer in any age range.
• For a serum PSA value between 4.0 and
10.0 ng/mL, using a % free PSA
threshold of <25% allowed detection of
95% of cancers while eliminating 20%
unnecessary biopsies.
23. Powerpoint Templates
Page 23
• Volume-based PSA parameters
evaluated to reduce confounding from
BPH.
• These include:
PSA density (PSAD; PSA divided by
prostate volume),
complexed PSA density (complexed
PSA divided by prostate volume), and
PSA transition zone density (PSA
divided by transition zone volume).
24. Powerpoint Templates
Page 24
• PSA levels between 4 and 10 ng/mL
and a normal DRE:
PSAD ≥ 0.15- prostate biopsy
recommended.
PSA transition zone volume was the
parameter with highest overall
sensitivity & specificity.
25. Powerpoint Templates
Page 25
PSA Dynamics/PSA Velocity(PSAV):
• Rate of change in PSA.
• With PSA levels between 4-10 ng/mL, PSAV
≥ 0.75 ng/mL/year: a specific marker for the
presence of prostate cancer.
• In PSA <4, PSAV > 0.5ng/mL/yr is
significant.
• PSAV may play a role in the prediction of life-
threatening prostate cancer .
• A PSAV > 0.35 ng/mL/year 10-15 years prior
to diagnosis- fivefold increased risk of life-
threatening prostate cancer more than a decade
later.
29. Powerpoint Templates
Page 29
Cleansing enema:
• decreases the amount of feces in the
rectum, thereby producing a superior
acoustic window for prostate
imaging.
• may reduce bacterial seeding of the
prostate.
30. Powerpoint Templates
Page 30
Analgesia:
• Topical lidocaine jelly.
• Infiltration anesthesia around nerve
bundles.
• Direct infiltration(Intraprostatic
injection).
• Skin & subcut.infiltration for
transperineal biopsy.
31. Powerpoint Templates
Page 31
• Left lateral decubitus position with knees
and hips flexed 90 degrees.
• Lithotomy position preferred for
transperineal biopsies, brachytherapy
treatment planning, or placement of fiducial
gold markers for external-beam therapy.
• Lithotomy position is preferred when color
Doppler imaging is used to identify areas of
hyperemia for targeted biopsy of the
prostate(distribution of color Doppler flow
within the prostate is dependent on patient
position)
32. Powerpoint Templates
Page 32
TRUS PROSTATE BIOPSY
TECHNIQUES
• Assess prostate volume.
• Prostate imaging in transverse &
sagittal planes(from base to apex).
• Note location and characteristics of any
lesions (i.e., hypoechoic, hyperechoic,
calcifications, contour abnormalities,
cystic structures).
33. Powerpoint Templates
Page 33
• A spring-driven, 18-gauge, needle core
biopsy device or biopsy gun, passed
through the needle guide attached to
the ultrasound probe.
• Biopsy gun advances the needle 0.5 cm
and samples subsequent 1.5 cm of
tissue with the tip extending 0.5 cm
beyond the area sampled.
37. Powerpoint Templates
Page 37
SEXTANT BIOPSY:
• one core, bilaterally,
each from base, mid,
and apex.
• samples both PZ &
TZ.
• Vast majority of
AdenoCa-
posterolateral PZ.
TRUS BIOPSY SCHEMES
38. Powerpoint Templates
Page 38
EXTENDED CORE BIOPSY
SCHEMES
• Improved cancer detection rates by
incorporating additional laterally
directed cores into the standard
systematic sextant technique.
• At present, 6 cores are considered
inadequate for routine prostate
biopsy for cancer detection.
39. Powerpoint Templates
Page 39
• TZ and SVs are not routinely sampled(low
yields for cancer detection at initial biopsy).
• TZ and anteriorly directed biopsies may
occasionally prove necessary to diagnose
prostate cancer in patients with persistently
elevated PSA levels and prior negative
biopsies.
• A role for TZ biopsies in men with gland size
> 50 mL, with an additional yield of 15%
cancer detection.
40. Powerpoint Templates
Page 40
• Seminal vesicle biopsy is not routinely
performed unless there is a palpable
abnormality, when PSA value > 30, or
if brachytherapy is being considered.
41. Powerpoint Templates
Page 41
Various reported systematic biopsy schemes.
A, Sextant biopsy scheme originally proposed by Hodge and
associates (Hodge et al, 1989b)
B, The 10-core biopsy of Presti and coworkers (2000).
C, The 12-core, or double sextant, biopsy.
D, The 13-core “5-region biopsy” of Eskew and colleagues
44. Powerpoint Templates
Page 44
REPEAT PROSTATE BIOPSY
• Use of a 2nd
prostate biopsy in all cases
of a negative finding on initial biopsy is
justified.
• But 3rd
and 4th
repeat biopsies should
only be obtained in selected patients
with high suspicion of cancer and/or
poor prognostic factors on the 1st
or 2nd
biopsy.
45. Powerpoint Templates
Page 45
• Overall cancer detection rates for repeat
prostate needle biopsy with various biopsy
templates ranges from 10% - 38%.
• Indications for a repeat prostate biopsy
include the following:
1) A highly suspicious DRE (digital rectal
examination)
2) A persistently rising serum PSA (> 0.4 –
0.75 ng/ml/yr.)
3) A low free PSA (certainly < 10%, maybe <
22% - 25%)
4) Presence of PIN or atypia on prior biopsy
47. Powerpoint Templates
Page 47
ADVANCED USG TECHNIQUES
FOR PROSTATE IMAGING
COLOR & POWER DOPPLER TRUS:
• Color Doppler imaging is based on
the frequency shift in the reflected
sound waves from the frequency of
insonation.
• depicts the velocity of blood flow in
a directionally dependent manner.
48. Powerpoint Templates
Page 48
• Color assignment is based on the direction
of blood flow related to the orientation of
the transducer receiving the signal; flow
toward the transducer- red and flow away
in shades of blue; color is not specific for
arterial or venous flow.
49. Powerpoint Templates
Page 49
Transrectal
ultrasonography.
• Top image, solid white arrow
depicts hypoechoic lesion
within the peripheral zone
concerning for prostate cancer.
• Lower image depicts
hypervascular area seen with
color Doppler imaging, yellow
and red area corresponds to the
hypoechoic area seen on the
grayscale ultrasonography
above.
50. Powerpoint Templates
Page 50
POWER DOPPLER IMAGING
(enhanced color Doppler, color
amplitude imaging [CAI], or color
angiography)
• uses amplitude shift to detect flow in
a velocity and directionally
independent manner.
• Advantages: ability to detect slower
flow and to have less reliance on the
Doppler angle, making it more
suitable for detection of prostate
cancer neovascularity.
51. Powerpoint Templates
Page 51
A. Color Doppler transrectal ultrasonography (TRUS) and
B. Power Doppler TRUS identify a Gleason 4 + 4 = 8
adenocarcinoma in the left midgland
52. Powerpoint Templates
Page 52
• Patients with detectable color Doppler
flow within their dominant tumor at the
time of TRUS-guided biopsy are at a
10-fold increased risk for PSA
recurrence after radical retropubic
prostatectomy.
53. Powerpoint Templates
Page 53
CONTRAST ENHANCED TRUS(CE-TRUS):
• Intravenous microbubble ultrasound contrast
agents, infused systemically during gray-scale and
TRUS Doppler imaging amplify flow signals within
the microvasculature of prostate tumors, allowing
selective visualization of malignant foci.
• These agents increase the echogenicity of the
intravascular space on grey-scale imaging and
provide a dramatic visible increase in the Doppler
signal.
• These are constructed with air or higher-molecular-
weight gas agents encapsulated (albumin or
polymer hard shell, lipid- or surfactant-coated) for
longevity.
54. Powerpoint Templates
Page 54
• CE-TRUS + 3D IMAGE
RECONSTRUCTION of enhanced
power doppler.
• GREY-SCALE HARMONIC imaging:
better spatial & temporal resolution.
• FLASH REPLENISHMENT
IMAGING: improved visualisation of
vessels.
55. Powerpoint Templates
Page 55
Unenhanced color (A) transrectal ultrasonography (TRUS) and power Doppler (B)
TRUS fail to detect evidence of an underlying malignancy. After infusion of a
microbubble contrast agent, color (C) TRUS and power Doppler (D) TRUS
demonstrate an area of increased flow in the left midgland that proved to be a Gleason
3 + 4 = 7 adenocarcinoma on targeted biopsy
56. Powerpoint Templates
Page 56
OTHER TECHNIQUES
ARTIFICIAL NEURAL NETWORKS
ELASTOGRAPHY:
• New sonography technique.
• employs real-time sonographic imaging of
the prostate at baseline and under varying
degrees of compression.
• Through computerized calculations,
differences in displacement between
ultrasonic images from baseline and during
compression may be visualized, and regions
with decreased tissue elasticity may be
tagged as suggestive of malignancy.
57. Powerpoint Templates
Page 57
Elastography demonstrates an area of decreased compliance in the right base
consistent with an underlying malignancy (blue near arrow). Note color scale
in upper right corner indicating relative tissue “firmness.” Targeted biopsy of
this region revealed a Gleason 4 + 4 = 8 adenocarcinoma
58. Powerpoint Templates
Page 58
ENDORECTAL MRI & MR
SPECTROSCOPIC IMAGING(MRSI):
• MRSI identifies biochemical changes
within the tissue that may predate the
appearance of histological changes.
• MRSI suggestive of malignancy may
not have biopsy detectable PCa at the
time of MRSI but may develop
histological cancer at a later date.